ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡µÄ¡°ÀÖÒâ±£?¡±£¨ÂØ¿¨Ä¹£©ÔÚÖйúÉÏÊÐ

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

Öйú½ôËæÃÀ¹úºÍÈÕ±¾Ö®ºó£¬³ÉΪµÚÈý¸ö¡°ÀÖÒâ±£?¡±ÉÏÊйú¼Ò

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼£¬ÈËÔ´»¯¿¹¿ÉÈÜÐÔ¾Û¼¯µí·ÛÑùÂÑ°×-¦Â£¨A¦Â£©µ¥¿Ë¡¿¹ÌåÀÖÒâ±£?£¨ÂØ¿¨Ä¹£©ÔÚÖйúÉÏÊС£¸ÃÒ©Æ·ÓÚ2024Äê1Ô»ñµÃÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼ÓÃÓÚÖÎÁÆÓÉ°¢¶û´Äº£Ä¬²¡ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍ°¢¶û´Äº£Ä¬²¡Çá¶È³Õ´ô¡£ÖйúÊǼÌÃÀ¹úºÍÈÕ±¾Ö®ºóµÚÈý¸öÉÏÊÐÂØ¿¨Ä¹µÄ¹ú¼Ò¡£

 

ÂØ¿¨Ä¹¿ÉÒÔÑ¡ÔñÐÔ½áºÏ¿ÉÈÜÐÔA¦Â¾Û¼¯Ì壨ԭÏËά*£©£¬ÒÔ¼°ADÖÐA¦Â°ß¿éµÄÖ÷ÒªÉí·Ö¡ª¡ª²»ÈÜÐÔA¦Â¾Û¼¯Ì壨ÏËά£©£¬´Ó¶ø¼õÉÙ´óÄÔÖеÄA¦ÂÔ­ÏËάºÍA¦Â°ß¿é¡£ÂØ¿¨Ä¹ÊÇÊ׸öÒ²ÊÇΨһһ¸ö±»ÍêÈ«Åú×¼µÄͨ¹ý¸Ã»úÖƽµµÍ¼²²¡½øÕ¹ËٶȲ¢¼õ»ºÈÏÖªºÍ´óÄÔ¹¦Ð§Ë¥Í˵ÄÖÎÁÆÒªÁì¡£

 

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ô¤¼Æ£¬2024ÄêÖйúÔ¼ÓÐ1700ÍòÓÉ°¢¶û´Äº£Ä¬²¡ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶È³Õ´ôµÄ»¼Õߣ¬ÕâÒ»Êý×ÖÔ¤¼Æ½«Ëæ×ÅÈË¿ÚÀÏÁ仯¶ø²»Í£Ôö¼Ó¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚÖйúÏúÊ۸òúÎ²¢Í¨¹ýרҵµÄÒ½Ò©´ú±íÌṩÐÅÏ¢·þÎñÊÂÇ飬ͬʱ»¹½«ÖÂÁ¦ÓÚ´òÔìÒ»¸öÆæÌصġ¢ÏßÉÏÏßÏÂÏà½áºÏµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡Õï¶ÏºÍÖÎÁÆ·¾¶¡£ÎÒÃǽ«ÓëÉ̱£¹«Ë¾¡¢Ìå¼ì»ú¹¹ºÍÑøÀÏ»ú¹¹µÈ¿ªÕ¹ºÏ×÷£¬¹ã·ºÌṩ¼²²¡Ðû´«ºÍÔ¤¼ì»ú»á£¬ÃãÀø¸ß·çÏÕÈËȺ¼°Ô絽ר¿ÆÒ½Ôº¾ÍÕ»òתÕïµ½Ó뾩¶«½¡¿µºÏ×Ê¿ª·¢µÄÔÚÏß½¡¿µÆ½Ì¨¡°Òø·¢Í¨¡±**£¬ “Òø·¢Í¨”ƽ̨ÌṩһϵÁбã½ÝµÄ·þÎñ£¬°üÂÞ£ºËÄÖÜÒ½ÔººÍר¼ÒµÄÐÅÏ¢¡¢ ÔÚÏßÒ½ÁÆ×ÉѯºÍÖÎÁƺó¸ú×Ù·þÎñµÈ¡£”Òø·¢Í¨ “Ä¿Ç°ÓµÓÐÔ¼ 300,000 Ãû×¢²áÓû§ºÍ 6,000 Ãû×¢²áÒ½Éú£¬½éÉÜËÄÖÜÒ½ÔººÍר¼ÒµÄÐÅÏ¢£¬²¢ÌṩÔÚÏßÒ½ÁÆ×ÉѯºÍ LEQEMBI ÖÎÁƺóµÄ¸ú×Ù·þÎñ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾»¹ÖÂÁ¦ÓÚÀûÓÃѪҺÉúÎï±êÖ¾ÎïΪÔçÆÚ°¢¶û´Äº£Ä¬²¡µÄÃ÷È·Õï¶ÏÌṩ¿Æѧ֤¾Ý¡£

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

 

ÔÚÖйú£¬ÂØ¿¨Ä¹½«Ê×ÏÈÔÚ×Ô·ÑÊг¡½øÐÐÏúÊÛ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Ð¯ÊÖÒ»¼Ò´óÐÍÒ½ÁƱ£ÏÕ¹«Ë¾£¬¿ª·¢²¢ÍƳöÒ»¿îרÃÅÕë¶Ô°¢¶û´Äº£Ä¬²¡µÄÒ½ÁƱ£Ïռƻ®£¬ÁýÕÖ²¿ÃÅÒ½ÁÆÓöÈ¡£

 

ͨ¹ýÒÔÉÏ´ëÊ©£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖÂÁ¦ÓÚÔÚÖйúÍƶ¯°¢¶û´Äº£Ä¬²¡µÄÔç·¢ÏÖ¡¢ÔçÕï¶Ï¡¢ÔçÖÎÁÆ£¬¹¹½¨ÀÏÄê³Õ´ôÉú̬ϵͳ£¬Ö§³ÖÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼Õß “ÏíÊÜ×î³äʵµÄÈËÉú”¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

*Ô­ÏËά±»ÈÏÊǵ¼ÖÂAD»¼ÕßµÄÄÔËðÉ˵ÄÔªÐ×£¬ÆäËùº¬¶¾ÐÔÊÇA¦ÂÖÐ×î´óµÄ£¬ÔÚÓëÕâÖÖ½øÐÐÐÔË¥ÈõµÄ¼²²¡Ïà¹ØµÄÈÏ֪˥ÍËÖÐÆðÖ÷Òª×÷ÓÃ1¡£Ô­ÏËά¶Ô´óÄÔÉñ¾­ÔªÔì³ÉËðÉË£¬½ø¶øͨ¹ý¶àÖÖ»úÖƶÔÈÏÖª¹¦Ð§·¢Éú¸ºÃæÓ°Ï죬²»½öÔö¼ÓÁ˲»ÈÜÐԦ°߿éµÄÐγÉ£¬¶øÇÒÔö¼ÓÁ˶ÔÄÔϸ°ûĤºÍÉñ¾­Ï¸°ûÖ®¼ä»òÉñ¾­Ï¸°ûÓëÆäËûϸ°ûÖ®¼äͨ±¨ÐźŵÄÁ¬½ÓµÄÖ±½ÓËðÉË¡£¼õÉÙÔ­ÏËά¿É¼õÉÙ¶Ô´óÄÔÉñ¾­ÔªµÄËðÉ˺ÍÈÏÖª¹¦Ð§ÕÏ°­À´×èÖ¹°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹2¡£

 

**Òø·¢Í¨ÊǾ©ÒÃÎÀÏí£¨ÉϺ££©½¡¿µ¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾µÄÏßÉÏÒµÎñ£¬¸Ã¹«Ë¾ÊÇÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÓ뾩¶«½¡¿µµÄºÏ×ÊÆóÒµ¡£

 

ýÌåÁªÂ磺

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾£¨Öйú£©Í¶×ÊÓÐÏÞ¹«Ë¾¹«¹²¹Øϵ²¿
TEL: +86 (0)21-24192888
PR@eisai.com.cn

 

?

²Î¿¼ÎÄÏ×£º

  1. Amin L, Harris DA. A¦Â receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
  2. Ono K, Tsuji M. Protofibrils of Amyloid-¦Â are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.